These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 22286764)

  • 21. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
    Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
    FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
    Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
    PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
    Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
    Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
    Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
    Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
    Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
    Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
    Yi B; Yang J; Wang L
    Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive auto-regulation of MYCN in human neuroblastoma.
    Suenaga Y; Kaneko Y; Matsumoto D; Hossain MS; Ozaki T; Nakagawara A
    Biochem Biophys Res Commun; 2009 Dec; 390(1):21-6. PubMed ID: 19766596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
    Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
    Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NeuroD1 promotes neuroblastoma cell growth by inducing the expression of ALK.
    Lu F; Kishida S; Mu P; Huang P; Cao D; Tsubota S; Kadomatsu K
    Cancer Sci; 2015 Apr; 106(4):390-6. PubMed ID: 25652313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
    Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
    Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
    Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
    Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.